CA2050045C - Pharmaceutical, vaginal applicable preparation and a process for its preparation - Google Patents
Pharmaceutical, vaginal applicable preparation and a process for its preparationInfo
- Publication number
- CA2050045C CA2050045C CA002050045A CA2050045A CA2050045C CA 2050045 C CA2050045 C CA 2050045C CA 002050045 A CA002050045 A CA 002050045A CA 2050045 A CA2050045 A CA 2050045A CA 2050045 C CA2050045 C CA 2050045C
- Authority
- CA
- Canada
- Prior art keywords
- weight
- nonoxynol
- component
- process according
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The pharmaceutical, vaginal applicable preparation is characterized in that it contains, homogeneously sub-divided, at least one in water soluble polyvinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexual transmissible or transmitted, respectively, diseases, and/or for vaginal affections, and occasionally one or more auxiliary agent(s), and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm, especially from 0.06 to 0.2 mm, preferably from 0.07 to 0.15 mm.
Description
.,~ 1 Z05~
Pharmaceutical. vaginal applicable preparation and a process for its preparation Field of the invention The present invention is directed to a pharma-ceutical, vaginal applicable preparation and to a pro-cess for its preparation.
Background of the invention For the pharmaceutical treatment of vaginal diseases are used usually vaginal tablets, ointments, gels, foams and ovuli. Each of these administrative forms has advantages and disadvantages. From the disad-vantages are mentioned: bad decomposition of the prepa-ration, foreign body feeling, bad distribution of the respective active component in the vaginal mucosa, com-plicated dosage, for example by means of an applicator.A foam may cause an unpleasant feeling and thus may be refused because of objective and/or subjective reasons.
Furthermore, it is known a so-called C-film for the pre-vention of pregnancy.
Summary of the invention It is an object of the present invention to provide a new galenic form, i.e. a film for the propor-tioned release of the active components for the local treatment of sexual transmissible or transmitted, respectively, diseases, and/or for vaginal affections.
This new galenic form shall distribute the active compo-nents on the vaginal mucosa relatively quick, good and uniform. In addition, also the stability of the active 2 20~ 5 compounds, which are present in the film, shall be in-creased.
These objects are obtained in an excellent way with the inventive preparation.
It is also an object of the present invention to provide a process for preparing said inventive prepa-ration.
The inventive pharmaceutical, vaginal appli-cable preparation is characterized in that it contains, homogeneously sub-divided, at least one in water soluble polyvinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexual transmissible or transmitted, respectively, diseases, and/or for vaginal affections, and occasio-nally one or more auxiliary agent(s), and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm, especially from 0.06 to 0.2 mm, preferably from 0.07 to 0.15 mm.
The inventive procress is characterized in that at least one in water soluble polyvinyl alcohol, at least one component A, selected from the group consis-ting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexual transmis-sible or transmitted, respectively, diseases, and/or for vaginal affections, and occasionally one or more auxi-liary agent(s), are mixed with water, and occasionally with at least one organic solvent, and are homogeneously sub-divided under heating, for example to a temperature 4 ~ ~
of about 90~C, and in that the so obtained mixture is poured and in that finally the present solvents are re-moved.
Detailed description of the preferred embodiments Preferred embodiments of this invention are defined in the dependent claims.
In the following part possible embodiments for preparing said inventive preparation (film) are descri-bed.
A in water soluble polyvinyl alcohol, forexample Poval 205 of the firm Kuraray Co. Ltd., Japan, is mixed with at least one of said component A, for example a mixture of at least one nonoxynol, such as nonoxynols of the formula CgHlg--C6H4---~OCH2CH2 t~ OH
wherein n is an integer, preferably 9 or 10, and glycerin, and with water. This mixture is then hea-ted, for example to a temperature of about 90~C. It is preferred to filter the cooled solution, for example at a temperature of about 50~C. If the active component B
and the optional auxiliary agents are soluble in water, then they are dissolved in water and are added to the mixture preferably before the filtration. If the active component B and the optional auxiliary agents are not soluble in water, then they are added to the mixture af-ter said filtration, preferably under stirring, for example in the form of a suspension or an emulsion, whe-reby aqueous suspensions or aqueous emulsions are pre-2~5~ 5 ~_ 4 ferred. Water-in-oil microemulsions and oil-in-water microemulsions are also applicable. It is also possible to add an in water not soluble active component B and/or auxiliary agent to the filtered mixture in solid form, preferably under stirring, especially then when the sus-pension becomes homogenized. It is also possible to add the active component B and/or auxiliary agent, dissolved in at least one organic solvent, to the mixture.
In this kind of addition no separation of the phases between the organic solvent and water shall oc-cur. If necessary for the corrosion protection of film preparation devices the filmcasting solution may be buf-fered.
Said filtration is carried out in order to re-move impurities, which may occasionally be present, suchas water insoluble polymers of polyvinyl alcohol, dust and further foreign substances. In the case of absolu-tely pure and uniform products, the filtration can be omitted. The filmcasting solution must be homogeneous.
Occasionally present air bubbles can be removed by lea-ving the solution to rest or by treating under vacuum or by performing a gentle agitation.
This filmcasting solution can now be processed in many manners, in the conventional way, in order to obtain a film.
According to a first method, the filmcasting solution is batch poured into a tub which has the dimen-sions desired. Then, the water and the occasionally pre-sent organic solvents are removed by drying. The drying can be carried out, for instance, by means of hot air, coming from a suitable hair-dryer, or coming from a sui-2~
, " ~.
table thermic lamp, for example an infra-red lamp. The temperature used must be such that no component is che-mically transformed, especially decomposed, by the in-fluence of heat.
The film can now be subjected to an embossing, thus increasing its surface and gripping capacity. The film is finally cut and ancillary processed, for in-stance packed into bags, and if necessary made sterile by a suitable irratiation method.
According to a second method, the filmcasting solution is processed continuously in a filmcasting de-vice. Thereby the filmcasting solution is poured onto a continuous tape through a slot nozzle. The film support is usually a strip of chrome steel polished to obtain high brightness. When pouring, the viscosity of the filmcasting solution must be such as to flow still, but not to stop.
The used viscosity depends among other things on the type of machine. The continuous tape, coated with the filmcasting solution, enters a drying tunnel, where the water and the organic solvent, which is occasionally present, are removed. The temperature in the drying tun-nel must be such that no component is chemically trans-formed, especially decomposed, by the influence of heat.
At the end o~ the drying tunnel, the film contains only a few percents by weight of water, for example about 5 %
by weight of water. The desired film thickness can be controlled and regulated by using a computer. If, when starting, the film is too thin, then the slot nozzle is automatically opened a little bit. On the contrary, if the film is too thick, then the slot nozzle is closed a little bit.
6 ,~ 4 ~ -With regard to the embossing, cutting and type of packaging, reference is made to the above correspon-ding statements.
The component B for the local treatment of se-xual transmissible or transmitted, respectively, di-seases, and/or for vaginal affections is especially an active component for the local treatment of bacterial or viral infections, or an active component for the local treatment of diseases caused by fungus or trichomonas.
Examples are: benzalkonium chloride, neomy-cins, such as neomycin-B-sulfate, polymyxins, such as polymyxin-B-sulfate, econazole, econazole nitrate, metronidazole, miconazole and miconazole nitrate.
These and still further active compounds, including a placenta extract, may be mixed with a non-oxynol, for example a nonoxynol of the formula CgH1g - C6H4 ( 0CH2CH2tn OH
wherein n is an integer, preferably 9 or 10.
Nonoxynol-9 and nonoxynol-10 are preferred, especially then when these compounds fulfill the prescriptions ac-cording to USP 22.
The inventive preparation is very easy to be applied. It can, cut to the desired dimensions, for example 5 x 5 cm, be introduced into the vagina by a finger. A foreign body feeling, if any, is only felt in the first minutes. By the influence of body heat and/or due to secretions, which are present in the vagina, the active component(s) contained in the film exhibit a bet-ter and more homogenous actions, in comparison with x~
.~ ,..,..
~_ 7 other, above all solid galenic forms. The pharmaceutical effect to be obtained depends on the used combination of active components.
The following examples shall illustrate the present invention.
Example 1 Vaginal pre~aration aqainst bacterial infections A mixture of 4.53 kg of polyvinyl alcohol Po-val 205rM of the firm Kuraray Co, Ltd., Japan, 360 g ofglycerin, 2.16 kg of nonoxynol-9 and 600 g of benzalko-nium chloride was slowly warmed to a temperature of 90~C
in 17.35 kg of water under stirring. When all components had dissolved the slightly cloudy solution was cooled and filtered at a temperature of 50~C. The clear filtrate was allowed to stand at a temperature of 45~C
during 30 minutes, whereupon in the mixture no air bubbles were present. With this filmcasting solution was prepared on a filmcasting machine a homogeneous film with a thickness of 0,09 mm. The filmcasting solution was poured at a temperature of 40~C to 50~C.
Example 2 Vaqinal Preparation against trichomonas A mixture of 453 mg of polyvinyl alcohol Poval 205TMof the firm Kuraray Co, Ltd., Japan, 36 mg of glycerin, 216 mg of nonoxynol-9 and 100 mg of metronidazole was dissolved in 10 ml of water and heated to a temperature of 90~C under stirring. The slightly cloudy solution was cooled and filtered at a temperature of 50~C. This filtrate was poured into a rectangular tub (5 x 10 cm) and dried with a heat lamp (Biccatherm~M-lamp). There was obtained a homogeneous film having a thickness of 0.075 mm.
Example 3 Vaqinal Preparation for the control of fungus A mixture of 3.01 kg of polyvinyl alcohol Po-val 205 of the firm Kuraray Co, Ltd., Japan, 240 g of glycerin and 1.0 kg of nonoxynol was slowly warmed to a temperature of 90~C under stirring in 13.35 kg of water.
The slightly cloudy solution was cooled and filtered at a temperature of 50OC. To this clear filtrate was added under stirring a slurry of 400 g of finally grinded econazole in 2.0 kg of water at a temperature of 35~C.
This mixture was slightly stirred at a temperature of 35~C during 30 minutes, whereupon in the mixture no more air bubbles were present. With this filmcasting solution was prepared a homogeneous film with a thickness of 0.07 mm on a filmcasting machine. The filmcasting solution was poured at a temperature of 35~C.
Exam~le 4 According to the teachings of example 2 but without said filtration a homogeneous film (8x8 cm) was prepared with the following components:
Polyvinyl alcohol Poval 205 T~ 435 mg Glycerin 35 mg Brij 35TM (a product of the firm ICI)300 mg Econazole nitrate 150 mg 920 mg At no place this film was thicker than 0.120 mm.
Exam~le 5 According to the teachings of example 2 but without said filtration a homogeneous film (5.3 x 6 cm) was prepared with the following components:
Polyvinyl alcohol Poval 205TM 255 mg Glycerin 20 mg Brij 35TM (a product of the firm ICI) 50 mg Metronidazole 100 mg 425 mg Z~&~5 At no place this film was thicker than 0.120 mm.
While there are shown and described present preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited thereto, but may be otherwise variously embodied and practiced within the scope of the following claims.
Pharmaceutical. vaginal applicable preparation and a process for its preparation Field of the invention The present invention is directed to a pharma-ceutical, vaginal applicable preparation and to a pro-cess for its preparation.
Background of the invention For the pharmaceutical treatment of vaginal diseases are used usually vaginal tablets, ointments, gels, foams and ovuli. Each of these administrative forms has advantages and disadvantages. From the disad-vantages are mentioned: bad decomposition of the prepa-ration, foreign body feeling, bad distribution of the respective active component in the vaginal mucosa, com-plicated dosage, for example by means of an applicator.A foam may cause an unpleasant feeling and thus may be refused because of objective and/or subjective reasons.
Furthermore, it is known a so-called C-film for the pre-vention of pregnancy.
Summary of the invention It is an object of the present invention to provide a new galenic form, i.e. a film for the propor-tioned release of the active components for the local treatment of sexual transmissible or transmitted, respectively, diseases, and/or for vaginal affections.
This new galenic form shall distribute the active compo-nents on the vaginal mucosa relatively quick, good and uniform. In addition, also the stability of the active 2 20~ 5 compounds, which are present in the film, shall be in-creased.
These objects are obtained in an excellent way with the inventive preparation.
It is also an object of the present invention to provide a process for preparing said inventive prepa-ration.
The inventive pharmaceutical, vaginal appli-cable preparation is characterized in that it contains, homogeneously sub-divided, at least one in water soluble polyvinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexual transmissible or transmitted, respectively, diseases, and/or for vaginal affections, and occasio-nally one or more auxiliary agent(s), and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm, especially from 0.06 to 0.2 mm, preferably from 0.07 to 0.15 mm.
The inventive procress is characterized in that at least one in water soluble polyvinyl alcohol, at least one component A, selected from the group consis-ting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexual transmis-sible or transmitted, respectively, diseases, and/or for vaginal affections, and occasionally one or more auxi-liary agent(s), are mixed with water, and occasionally with at least one organic solvent, and are homogeneously sub-divided under heating, for example to a temperature 4 ~ ~
of about 90~C, and in that the so obtained mixture is poured and in that finally the present solvents are re-moved.
Detailed description of the preferred embodiments Preferred embodiments of this invention are defined in the dependent claims.
In the following part possible embodiments for preparing said inventive preparation (film) are descri-bed.
A in water soluble polyvinyl alcohol, forexample Poval 205 of the firm Kuraray Co. Ltd., Japan, is mixed with at least one of said component A, for example a mixture of at least one nonoxynol, such as nonoxynols of the formula CgHlg--C6H4---~OCH2CH2 t~ OH
wherein n is an integer, preferably 9 or 10, and glycerin, and with water. This mixture is then hea-ted, for example to a temperature of about 90~C. It is preferred to filter the cooled solution, for example at a temperature of about 50~C. If the active component B
and the optional auxiliary agents are soluble in water, then they are dissolved in water and are added to the mixture preferably before the filtration. If the active component B and the optional auxiliary agents are not soluble in water, then they are added to the mixture af-ter said filtration, preferably under stirring, for example in the form of a suspension or an emulsion, whe-reby aqueous suspensions or aqueous emulsions are pre-2~5~ 5 ~_ 4 ferred. Water-in-oil microemulsions and oil-in-water microemulsions are also applicable. It is also possible to add an in water not soluble active component B and/or auxiliary agent to the filtered mixture in solid form, preferably under stirring, especially then when the sus-pension becomes homogenized. It is also possible to add the active component B and/or auxiliary agent, dissolved in at least one organic solvent, to the mixture.
In this kind of addition no separation of the phases between the organic solvent and water shall oc-cur. If necessary for the corrosion protection of film preparation devices the filmcasting solution may be buf-fered.
Said filtration is carried out in order to re-move impurities, which may occasionally be present, suchas water insoluble polymers of polyvinyl alcohol, dust and further foreign substances. In the case of absolu-tely pure and uniform products, the filtration can be omitted. The filmcasting solution must be homogeneous.
Occasionally present air bubbles can be removed by lea-ving the solution to rest or by treating under vacuum or by performing a gentle agitation.
This filmcasting solution can now be processed in many manners, in the conventional way, in order to obtain a film.
According to a first method, the filmcasting solution is batch poured into a tub which has the dimen-sions desired. Then, the water and the occasionally pre-sent organic solvents are removed by drying. The drying can be carried out, for instance, by means of hot air, coming from a suitable hair-dryer, or coming from a sui-2~
, " ~.
table thermic lamp, for example an infra-red lamp. The temperature used must be such that no component is che-mically transformed, especially decomposed, by the in-fluence of heat.
The film can now be subjected to an embossing, thus increasing its surface and gripping capacity. The film is finally cut and ancillary processed, for in-stance packed into bags, and if necessary made sterile by a suitable irratiation method.
According to a second method, the filmcasting solution is processed continuously in a filmcasting de-vice. Thereby the filmcasting solution is poured onto a continuous tape through a slot nozzle. The film support is usually a strip of chrome steel polished to obtain high brightness. When pouring, the viscosity of the filmcasting solution must be such as to flow still, but not to stop.
The used viscosity depends among other things on the type of machine. The continuous tape, coated with the filmcasting solution, enters a drying tunnel, where the water and the organic solvent, which is occasionally present, are removed. The temperature in the drying tun-nel must be such that no component is chemically trans-formed, especially decomposed, by the influence of heat.
At the end o~ the drying tunnel, the film contains only a few percents by weight of water, for example about 5 %
by weight of water. The desired film thickness can be controlled and regulated by using a computer. If, when starting, the film is too thin, then the slot nozzle is automatically opened a little bit. On the contrary, if the film is too thick, then the slot nozzle is closed a little bit.
6 ,~ 4 ~ -With regard to the embossing, cutting and type of packaging, reference is made to the above correspon-ding statements.
The component B for the local treatment of se-xual transmissible or transmitted, respectively, di-seases, and/or for vaginal affections is especially an active component for the local treatment of bacterial or viral infections, or an active component for the local treatment of diseases caused by fungus or trichomonas.
Examples are: benzalkonium chloride, neomy-cins, such as neomycin-B-sulfate, polymyxins, such as polymyxin-B-sulfate, econazole, econazole nitrate, metronidazole, miconazole and miconazole nitrate.
These and still further active compounds, including a placenta extract, may be mixed with a non-oxynol, for example a nonoxynol of the formula CgH1g - C6H4 ( 0CH2CH2tn OH
wherein n is an integer, preferably 9 or 10.
Nonoxynol-9 and nonoxynol-10 are preferred, especially then when these compounds fulfill the prescriptions ac-cording to USP 22.
The inventive preparation is very easy to be applied. It can, cut to the desired dimensions, for example 5 x 5 cm, be introduced into the vagina by a finger. A foreign body feeling, if any, is only felt in the first minutes. By the influence of body heat and/or due to secretions, which are present in the vagina, the active component(s) contained in the film exhibit a bet-ter and more homogenous actions, in comparison with x~
.~ ,..,..
~_ 7 other, above all solid galenic forms. The pharmaceutical effect to be obtained depends on the used combination of active components.
The following examples shall illustrate the present invention.
Example 1 Vaginal pre~aration aqainst bacterial infections A mixture of 4.53 kg of polyvinyl alcohol Po-val 205rM of the firm Kuraray Co, Ltd., Japan, 360 g ofglycerin, 2.16 kg of nonoxynol-9 and 600 g of benzalko-nium chloride was slowly warmed to a temperature of 90~C
in 17.35 kg of water under stirring. When all components had dissolved the slightly cloudy solution was cooled and filtered at a temperature of 50~C. The clear filtrate was allowed to stand at a temperature of 45~C
during 30 minutes, whereupon in the mixture no air bubbles were present. With this filmcasting solution was prepared on a filmcasting machine a homogeneous film with a thickness of 0,09 mm. The filmcasting solution was poured at a temperature of 40~C to 50~C.
Example 2 Vaqinal Preparation against trichomonas A mixture of 453 mg of polyvinyl alcohol Poval 205TMof the firm Kuraray Co, Ltd., Japan, 36 mg of glycerin, 216 mg of nonoxynol-9 and 100 mg of metronidazole was dissolved in 10 ml of water and heated to a temperature of 90~C under stirring. The slightly cloudy solution was cooled and filtered at a temperature of 50~C. This filtrate was poured into a rectangular tub (5 x 10 cm) and dried with a heat lamp (Biccatherm~M-lamp). There was obtained a homogeneous film having a thickness of 0.075 mm.
Example 3 Vaqinal Preparation for the control of fungus A mixture of 3.01 kg of polyvinyl alcohol Po-val 205 of the firm Kuraray Co, Ltd., Japan, 240 g of glycerin and 1.0 kg of nonoxynol was slowly warmed to a temperature of 90~C under stirring in 13.35 kg of water.
The slightly cloudy solution was cooled and filtered at a temperature of 50OC. To this clear filtrate was added under stirring a slurry of 400 g of finally grinded econazole in 2.0 kg of water at a temperature of 35~C.
This mixture was slightly stirred at a temperature of 35~C during 30 minutes, whereupon in the mixture no more air bubbles were present. With this filmcasting solution was prepared a homogeneous film with a thickness of 0.07 mm on a filmcasting machine. The filmcasting solution was poured at a temperature of 35~C.
Exam~le 4 According to the teachings of example 2 but without said filtration a homogeneous film (8x8 cm) was prepared with the following components:
Polyvinyl alcohol Poval 205 T~ 435 mg Glycerin 35 mg Brij 35TM (a product of the firm ICI)300 mg Econazole nitrate 150 mg 920 mg At no place this film was thicker than 0.120 mm.
Exam~le 5 According to the teachings of example 2 but without said filtration a homogeneous film (5.3 x 6 cm) was prepared with the following components:
Polyvinyl alcohol Poval 205TM 255 mg Glycerin 20 mg Brij 35TM (a product of the firm ICI) 50 mg Metronidazole 100 mg 425 mg Z~&~5 At no place this film was thicker than 0.120 mm.
While there are shown and described present preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited thereto, but may be otherwise variously embodied and practiced within the scope of the following claims.
Claims (36)
1. A pharmaceutical, vaginal applicable preparation, characterized in that it contains, homogeneously sub-divided, at least one water soluble polyvinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B, whereby this component B is active for at least one of the local treatment of sexual transmissible or transmitted, respectively, diseases, and vaginal affections, and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm.
2. The preparation according to claim 1, characterized in that it contains one or more auxiliary agent(s).
3. The preparation according to claim 1, characterized in that the film has a thickness of the layer from 0.06 to 0.2 mm.
4. The preparation according to claim 3, characterized in that the film has a thickness of the layer from 0.07 to 0.15 mm.
5. The preparation according to claim 1, characterized in that the active component B is an active component for the local treatment of bacterial or viral infections, or an active component for the local treatment of diseases caused by fungus or trichomonas, or an active component for the treatment of vaginal mucosa affections, whereby these active components are optionally mixed with at least one nonoxynol.
6. The preparation according to claim 1, characterized in that the component B is selected from the group consisting of benzalkonium chloride, a neomycin, a polymyxin, econazole, econazole nitrate, metronidazole, miconazole, miconazole nitrate and a placenta extract.
7. The preparation according to claim 6, characterized in that the neomycin is neomycin-B-sulfate and that the polymyxin is polymyxin-B-sulfate.
8. The preparation according to claim 5, characterized in that the nonoxynol has the formula C9H19~ C6H4 ~ OCH2 CH2~ OH
wherein n is the integer 9 or 10.
wherein n is the integer 9 or 10.
9. The preparation according to claim 1, characterized in that the component A is selected from polyoxyethylene ethers of fatty alcohols, monovalent alcohols, and polyvalent alcohols.
10. The preparation according to claim 1, characterized in that the component A is selected from the group consisting of lauryl alcohol, a nonoxynol, propylene glycol and glycerin.
11. The preparation according to claim 10, characterized in that the lauryl alcohol is Brij 30TM or Brij 35TM and that the nonoxynol is nonoxynol-9 or nonoxynol-10.
12. The preparation according to claim 1, characterized in that the component A is a mixture of a nonoxynol and glycerin.
13 13. The preparation according to claim 2, characterized in that it contains from 50 to 70 % by weight of a polyvinyl alcohol, from 15 to 35 % by weight of nonoxynol, from 3 to 8 % by weight of glycerin, and up to 15 % by weight of active component B, whereby the total of all components, including the auxiliary agent(s), gives always 100 % by weight.
14. The preparation according to claim 13, characterized in that it contains from 55 to 65 % by weight of a polyvinyl alcohol, from 20 to 30 % by weight of nonoxynol, 5 % by weight of glycerin, and up to 15 %
by weight of active component B, whereby the total of all components, including the auxiliary agent(s), gives always 100 % by weight.
by weight of active component B, whereby the total of all components, including the auxiliary agent(s), gives always 100 % by weight.
15. The preparation according to claim 2, characterized in that the auxiliary agents are selected from the group consisting of stabilizers, plasticizers, buffers, antioxidants, perfumes and dyes, and in that they are present always in active concentrations.
16. The preparation according to claim 1, characterized in that the surface of the film is increased by means of embossing.
17. A process for preparing a pharmaceutical, vaginal applicable preparation, characterized in that at least one water soluble polyvinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B, whereby this component B is active for at least one of the local treatment of sexual transmissible or transmitted, respectively, diseases, and vaginal affections, are mixed with water and are homogeneously sub-divided under heating, and in that the so obtained mixture is poured and in that finally the present solvents are removed.
18. The process according to claim 17, characterized in that the mixture comprises one or more auxiliary agent(s).
19. The process according to claim 17, characterized in that the components are mixed with water and at least one organic solvent.
20. The process according to claim 17, characterized in that the heating is done to a temperature of about 90°C.
21. The process according to claim 17, characterized in that the active component B is an active component for the local treatment of bacterial or viral infections, or an active component for the local treatment of diseases caused by fungus or trichomonas, or an active component for the treatment of vaginal mucosa affections, whereby these active components are optionally mixed with at least one nonoxynol.
22. The process according to claim 17, characterized in that the component B is selected from the group consisting of benzalkonium chloride, a neomycin, a polymyxin, econazole, econazole nitrate, metronidazole, miconazole, miconazole nitrate and a placenta extract.
23. The process according to claim 22, characterized in that the neomycin is neomycin-B-sulfate and that the polymyxin is polymyxin-B-sulfate.
24. The process according to claim 21, characterized in that the nonoxynol has the formula C9H19~C6H4 ~ OCH2 CH2 ~ OH
wherein n is the integer 9 or 10.
wherein n is the integer 9 or 10.
25. The process according to claim 17, characterized in that the component A is selected from polyoxyethylene ethers of fatty alcohols, monovalent alcohols, and polyvalent alcohols.
26. The process according to claim 17, characterized in that the component A is selected from the group consisting of lauryl alcohol, a nonoxynol, propylene glycol and glycerin.
27. The process according to claim 26, characterized in that the lauryl alcohol is Brij 30TM or Brij 35TM and that the nonoxynol is nonoxynol-9 or nonoxynol-10.
28. The process according to claim 17, characterized in that the component A is a mixture of a nonoxynol and glycerin.
29. The process according to claim 18, characterized in that the mixing proportion is adjusted in such a way, that the preparation contains from 50 to 70 % by weight of a polyvinyl alcohol, from 15 to 35 % by weight of nonoxynol, from 3 to 8 % by weight of glycerin, and up to 15 % by weight of active component B, whereby the total of all components, including the auxiliary agent(s), gives always 100 % by weight.
30. The process according to claim 18, characterized in that the mixing proportion is adjusted in such a way, that the preparation contains from 55 to 65 % by weight of a polyvinyl alcohol, from 20 to 30 % by weight of nonoxynol, 5 % by weight of glycerin, and up to 15 % by weight of active component B, whereby the total of all components, including the auxiliary agent(s), gives always 100 % by weight.
31. The process according to claim 18, characterized in that the auxiliary agents are selected from the group consisting of stabilizers, plasticizers, buffers, antioxidants, perfumes and dyes, and in that they are present always in active concentrations.
32. The process according to claim 17, characterized in that the mixture is filtrated before it is poured.
33. The process according to claim 17, characterized in that the preparation is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm.
34. The process according to claim 33, characterized in that the film has a thickness of the layer from 0.06 to 0.2 mm.
35. The process according to claim 34, characterized in that the film has a thickness of the layer from 0.07 to 0.15 mm.
36. The process according to claim 33, characterized in that the surface of the film is increased by means of embossing.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74910591A | 1991-08-23 | 1991-08-23 | |
| US07/749,105 | 1991-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2050045A1 CA2050045A1 (en) | 1993-02-24 |
| CA2050045C true CA2050045C (en) | 1999-04-06 |
Family
ID=25012278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002050045A Expired - Fee Related CA2050045C (en) | 1991-08-23 | 1991-08-27 | Pharmaceutical, vaginal applicable preparation and a process for its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2050045C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111617245A (en) * | 2020-07-04 | 2020-09-04 | 福州弘海生物科技有限公司 | Multi-purpose anti-inflammatory foam for female vagina |
-
1991
- 1991-08-27 CA CA002050045A patent/CA2050045C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2050045A1 (en) | 1993-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5380529A (en) | Pharmaceutical, vaginal applicable preparation and a process for its preparation | |
| US5912009A (en) | Fatty acid esters of glycolic acid and its salts | |
| DE60126017T2 (en) | A transdermal preparation containing hydrophilic or salted drug | |
| US4438139A (en) | Polymeric diffusion matrix containing estrogens | |
| JP2946098B2 (en) | Cosmetic or pharmaceutical composition containing microspheres of polymer or fatty substance loaded with at least one active product | |
| US3639575A (en) | Silver ion gel compositions and method of using the same | |
| JPH07309762A (en) | Ethylene/vinyl acetate base endermic matrix system for dosing estrogen and/or progestogen | |
| EP0641221A1 (en) | Anhydrous formulations for administering lipophilic agents | |
| JP3553174B2 (en) | Sheet pack | |
| CA2050045C (en) | Pharmaceutical, vaginal applicable preparation and a process for its preparation | |
| JP3908275B2 (en) | Cold seat | |
| IE912392A1 (en) | Pharmaceutical, vaginal applicable preparation | |
| AU2006210042A1 (en) | Karaya gum-based hydrophilic gel system for skin care | |
| JPH08506822A (en) | Formulations containing di- or triglycerol esters as active ingredients, which act on spotted and pimpled skin | |
| JPS593965B2 (en) | Manufacturing method for skin disease treatment patch | |
| JPH10500415A (en) | Transdermal delivery of antiepileptic drugs | |
| WO2003103630A1 (en) | Liposomal vitamin a and method of preparation | |
| JPS5957793A (en) | Protective agent for printing surface of planographic printing plate | |
| JPH1053527A (en) | Percutaneous absorbent preparation containing caffeine | |
| EP0461085A1 (en) | Pharmaceutical and/or cosmetic preparation | |
| CA2127218A1 (en) | Compositions for the treatment of inflammatory proliferative skin disease and their use | |
| JPS5910513A (en) | Pharmaceutical preparation of drug | |
| JPH07126164A (en) | Prolonged action antifungal agent | |
| WO2001049273A2 (en) | Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation | |
| JPS6113444B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed | ||
| MKLA | Lapsed |
Effective date: 20040827 |